|Videos|October 10, 2017

What Advantage Does Delafoxacin Have Over Other Fluoroquinolones?

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Sue Cammarata, MD, CMO of Melinta Therapeutics, explains the advantages that delafloxcin has over other available fluoroquinolones. When it comes to adverse events, other fluoroquinolones are known to cause heart arrhythmias, cause reactions in sunshine, as well as liver or sugar/glucose abnormalities, where delafloxcin does not.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.